Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD388 influenza challenge prophylaxis study in healthy adults
ISRCTN14841526Phase 2Completed
- Sponsor
- hVIVO
- Start
- Aug 2022
- Modality
- Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of retezrelvir in influenza (6 arms), sponsored by hVIVO. Primary endpoint: Viral load area under the curve by qRT-PCR. Started Aug 2022; status: completed.
02
Drugs
retezrelvir
03
Conditions
influenza
Beyond the preview
Go deeper on ISRCTN14841526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14841526.